
Jeremy Millar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1534308/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Large variation in radiation therapy fractionation for multiple myeloma in Australia. Asia-Pacific Journal of Clinical Oncology, 2023, 19, 149-157.	0.7	2
2	Predictors of realâ€world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormoneâ€sensitive prostate cancer. Internal Medicine Journal, 2022, 52, 1339-1346.	0.5	9
3	Changing pattern of radiation therapy for bone metastases in an Australian population-based cohort of men with prostate cancer. Clinical Genitourinary Cancer, 2022, 20, e7-e15.	0.9	1
4	Knowledge and insights from a maturing international clinical quality registry. Journal of the American Medical Informatics Association: JAMIA, 2022, 29, 964-969.	2.2	1
5	Large variation in conservative management of lowâ€risk prostate cancer in Australia and New Zealand. BJU International, 2022, 130, 17-19.	1.3	5
6	Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. Clinical Genitourinary Cancer, 2022, , .	0.9	1
7	Comparison of urinary and sexual patient-reported outcomes between open radical prostatectomy and robot-assisted radical prostatectomy: a propensity score matched, population-based study in Victoria. BMC Urology, 2022, 22, 18.	0.6	5
8	Quality indicators for radiation oncology. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 249-257.	0.9	36
9	Quantifying the effect email reminders have on patient reported outcome measure returns in a large prostate cancer registry. Journal of Patient-Reported Outcomes, 2022, 6, 19.	0.9	3
10	Radiation oncology peer review in Australia and New Zealand. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 258-266.	0.9	1
11	Mapping disadvantage: identifying inequities in functional outcomes for prostate cancer survivors based on geography. BMC Cancer, 2022, 22, 283.	1.1	2
12	Disparities in radiation therapy utilization for cancer patients in Victoria. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 830-839.	0.9	2
13	Codesigning a patient support portal with health professionals and men with prostate cancer: An action research study. Health Expectations, 2022, , .	1.1	1
14	Effects of a multicomponent resistance-based exercise program with protein, vitamin D and calcium supplementation on cognition in men with prostate cancer treated with ADT: secondary analysis of a 12-month randomised controlled trial. BMJ Open, 2022, 12, e060189.	0.8	2
15	Effect of Aspirin on Cancer Incidence and Mortality in Older Adults. Journal of the National Cancer Institute, 2021, 113, 258-265.	3.0	80
16	Geospatial and temporal variation of prostate cancer incidence. Public Health, 2021, 190, 7-15.	1.4	8
17	Trends in Conservative Management for Low-risk Prostate Cancer in a Population-based Cohort of Australian Men Diagnosed Between 2009 and 2016. European Urology Oncology, 2021, 4, 319-322.	2.6	20
18	Choosing Wisely in radiation therapy for breast cancer: Time lag in adoption of hypofractionated radiation therapy in Victoria. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 224-232.	0.9	6

#	Article	IF	CITATIONS
19	Patterns of primary staging for newly diagnosed prostate cancer in the era of prostate specific membrane antigen positron emission tomography: A populationâ€based analysis. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 649-654.	0.9	4
20	Musculoskeletal Responses to Exercise Plus Nutrition in Men with Prostate Cancer on Androgen Deprivation: A 12-Month RCT. Medicine and Science in Sports and Exercise, 2021, 53, 2054-2065.	0.2	8
21	Establishing a global quality of care benchmark report. Health Informatics Journal, 2021, 27, 146045822110157.	1.1	7
22	Patterns of care for prostate cancer treatment and improving outcomes – are national registries the answer?. BJU International, 2021, 128 Suppl 1, 6-8.	1.3	11
23	Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare Standards. Medical Journal of Australia, 2021, 214, 528-531.	0.8	2
24	Evolving Practice Pattern of Palliative Radiation Therapy for Bone Metastases from Lung Cancer in Australia. Clinical Oncology, 2021, 33, e530-e539.	0.6	2
25	Selfâ€reported lack of energy or feeling depressed 12Âmonths after treatment in men diagnosed with prostate cancer within a populationâ€based registry. Psycho-Oncology, 2021, , .	1.0	1
26	Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand. JAMA Network Open, 2021, 4, e2129647.	2.8	13
27	A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease. Cancers, 2021, 13, 5815.	1.7	7
28	Increasing use of postâ€mastectomy hypofractionated radiation therapy for breast cancer in Victoria. Journal of Medical Imaging and Radiation Oncology, 2021, , .	0.9	0
29	Variation in the Use of Single- Versus Multifraction Palliative Radiation Therapy for Bone Metastases in Australia. International Journal of Radiation Oncology Biology Physics, 2020, 106, 61-66.	0.4	15
30	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG) Tj ETQq0 0 0 rg 2020, 21, 1331-1340.	BT /Overlc 5.1	ock 10 Tf 50 3 197
31	The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs. Nature Reviews Urology, 2020, 17, 499-512.	1.9	15
32	External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost. Frontiers in Oncology, 2020, 10, 910.	1.3	3
33	A biochemical definition of cure after brachytherapy for prostate cancer. Radiotherapy and Oncology, 2020, 149, 64-69.	0.3	48
34	Extent and predictors of grade upgrading and downgrading in an Australian cohort according to the new prostate cancer grade groupings. Asian Journal of Urology, 2019, 6, 321-329.	0.5	7
35	The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment. Cancers, 2019, 11, 928.	1.7	5
36	Body size and dietary risk factors for aggressive prostate cancer: a case–control study. Cancer Causes and Control, 2019, 30, 1301-1312.	0.8	2

#	Article	IF	CITATIONS
37	Are We Choosing Wisely in Radiation Oncology Practice–Findings From an Australian Population-Based Study. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1012-1016.	0.4	11
38	Incident Chronic Kidney Disease After Radical Nephrectomy for Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e581-e591.	0.9	3
39	Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone. Brachytherapy, 2019, 18, 313-321.	0.2	22
40	Development of Technologic Solutions to Address Complex Local Requirements of an International Prostate Cancer Clinical Quality Registry. JCO Clinical Cancer Informatics, 2019, 3, 1-11.	1.0	2
41	Forecasting annual incidence and mortality rate for prostate cancer in Australia until 2022 using autoregressive integrated moving average (ARIMA) models. BMJ Open, 2019, 9, e031331.	0.8	17
42	The trajectory of patients who die from metastatic prostate cancer: a populationâ€based study. BJU International, 2019, 123, 19-26.	1.3	13
43	Androgen deprivation therapy use with postâ€prostatectomy radiotherapy in the Prostate Cancer Outcomes Registry Victoria. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 124-130.	0.9	0
44	Transition Points for the Routine Integration of Palliative Care in Patients With Advanced Cancer. Journal of Pain and Symptom Management, 2018, 56, 185-194.	0.6	31
45	Understanding the Relationship Between Interactive Optimisation and Visual Analytics in the Context of Prostate Brachytherapy. IEEE Transactions on Visualization and Computer Graphics, 2018, 24, 319-329.	2.9	18
46	Underâ€utilisation of highâ€doseâ€rate brachytherapy boost in men with intermediateâ€high risk prostate cancer treated with external beam radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 256-261.	0.9	12
47	Quality Indicators for Global Benchmarking of Localized Prostate Cancer Management. Journal of Urology, 2018, 200, 319-326.	0.2	11
48	Interpolation to define clinical tumor stage in prostate cancer using clinical description of digital rectal examination. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e412-e419.	0.7	1
49	In Regard to Yang etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1294-1295.	0.4	2
50	Development of Indicators to Assess Quality of Care for Prostate Cancer. European Urology Focus, 2018, 4, 57-63.	1.6	17
51	Australian validation of the Cancer of the Prostate Risk Assessment Postâ€Surgical score to predict biochemical recurrence after radical prostatectomy. ANZ Journal of Surgery, 2018, 88, E183-E188.	0.3	2
52	An integrated system for clinical treatment verification of HDR prostate brachytherapy combining source tracking with pretreatment imaging. Brachytherapy, 2018, 17, 111-121.	0.2	32
53	Early-onset baldness and the risk of aggressive prostate cancer: findings from a case–control study. Cancer Causes and Control, 2018, 29, 93-102.	0.8	6
54	Brachytherapyâ€based radiotherapy with androgen deprivation for management of highâ€risk prostate cancer – time to reverse the declining trend?. BJU International, 2018, 122, 5-6.	1.3	3

#	Article	IF	CITATIONS
55	Patterns of care and outcomes for men diagnosed with prostate cancer in Victoria: an update. ANZ Journal of Surgery, 2018, 88, 1037-1042.	0.3	13
56	Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method. Radiotherapy and Oncology, 2018, 128, 308-314.	0.3	12
57	OC-0170: Routine clinical treatment verification in HDR prostate brachytherapy with source tracking. Radiotherapy and Oncology, 2018, 127, S88.	0.3	0
58	Optimal Treatment for High-Risk Prostate Cancer. JAMA - Journal of the American Medical Association, 2018, 320, 404.	3.8	0
59	Active surveillance of men with low risk prostate cancer: evidence from the Prostate Cancer Outcomes Registry–Victoria. Medical Journal of Australia, 2018, 208, 439-443.	0.8	22
60	Radiobiological parameters in a tumour control probability model for prostate cancer LDR brachytherapy. Physics in Medicine and Biology, 2018, 63, 135011.	1.6	3
61	Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials Journal of Clinical Oncology, 2018, 36, 5018-5018.	0.8	7
62	The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period. Journal of Cancer Survivorship, 2017, 11, 329-338.	1.5	25
63	Activation of hip prostheses in high energy radiotherapy and resultant dose to nearby tissue. Journal of Applied Clinical Medical Physics, 2017, 18, 100-105.	0.8	2
64	Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: AÂSystematic Review of Prognostic Tool Accuracy and Validity. International Journal of Radiation Oncology Biology Physics, 2017, 98, 318-337.	0.4	10
65	Tools for Predicting Clinical and Patient-reported Outcomes in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review of Prognostic Accuracy and Validity. Clinical Genitourinary Cancer, 2017, 15, 629-634.e8.	0.9	5
66	Total and beverage-specific alcohol intake and the risk of aggressive prostate cancer: a case–control study. Prostate Cancer and Prostatic Diseases, 2017, 20, 305-310.	2.0	10
67	Population-based study of grade progression in patients who harboured Gleason 3Â+Â3. World Journal of Urology, 2017, 35, 1689-1699.	1.2	3
68	Trends in the surgical management of stage 1 renal cell carcinoma: findings from a populationâ€based study. BJU International, 2017, 120, 6-14.	1.3	19
69	3D catheter reconstruction in HDR prostate brachytherapy for pre-treatment verification using a flat panel detector. Physica Medica, 2017, 39, 121-131.	0.4	10
70	Tools for predicting patient-reported outcomes in prostate cancer patients undergoing radical prostatectomy: a systematic review of prognostic accuracy and validity. Prostate Cancer and Prostatic Diseases, 2017, 20, 378-388.	2.0	19
71	Optimum Tools for Predicting Clinical Outcomes in Prostate Cancer Patients Undergoing Radical Prostatectomy: A Systematic Review of Prognostic Accuracy and Validity. Clinical Genitourinary Cancer, 2017, 15, e827-e834.	0.9	16
72	PD47-11 OPTIMUM TOOLS FOR PREDICTING CLINICAL OUTCOMES IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY: AÂSYSTEMATIC REVIEW OF PROGNOSTIC ACCURACYÂAND VALIDITY. Journal of Urology, 2017, 197, .	0.2	1

#	Article	IF	CITATIONS
73	An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review. Radiation Oncology, 2017, 12, 56.	1.2	13
74	Ejaculatory frequency and the risk of aggressive prostate cancer: Findings from a case-control study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 530.e7-530.e13.	0.8	13
75	Decline in acute urinary toxicities with increased institutional experience: 15-year experience of permanent seed prostate brachytherapy in a single Australasian institution. Brachytherapy, 2017, 16, 313-322.	0.2	6
76	Distress and unmet needs during treatment and quality of life in early cancer survivorship: A longitudinal study of haematological cancer patients. European Journal of Haematology, 2017, 99, 423-430.	1.1	43
77	A Randomized Controlled Trial of an Additional Funding Intervention to Improve Clinical Trial Enrollment. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1104-1110.	2.3	3
78	Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncology, The, 2017, 18, 1192-1201.	5.1	45
79	Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a populationâ€based cohort of men with intermediate―and highâ€risk prostate cancer. BJU International, 2017, 120, 35-42.	1.3	17
80	The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers. Supportive Care in Cancer, 2017, 25, 3447-3456.	1.0	33
81	Cohort profile: the TrueNTH Global Registry - an international registry to monitor and improve localised prostate cancer health outcomes. BMJ Open, 2017, 7, e017006.	0.8	35
82	Men's perceptions of prostate cancer diagnosis and care: insights from qualitative interviews in Victoria, Australia. BMC Cancer, 2017, 17, 704.	1.1	14
83	Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial. Trials, 2017, 18, 451.	0.7	17
84	Quality of care achievements of the Prostate Cancer Outcomes Registry–Victoria. Medical Journal of Australia, 2016, 204, 319-319.	0.8	31
85	HIV and renal cell carcinoma: Experience in an Australian statewide HIV center. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 188-193.	0.7	10
86	A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease. BMC Cancer, 2016, 16, 607.	1.1	21
87	A method for verification of treatment delivery in HDR prostate brachytherapy using a flat panel detector for both imaging and source tracking. Medical Physics, 2016, 43, 2435-2442.	1.6	20
88	P331 Transition to Palliative Care for Patients with Metastatic Prostate Cancer: How Well Have We Integrated?. Journal of Pain and Symptom Management, 2016, 52, e150-e151.	0.6	1
89	P332 Exploring the Landscape of Palliative Care for People with Non-Hodgkin's Lymphoma: Do They Receive Quality End-of-Life Care?. Journal of Pain and Symptom Management, 2016, 52, e151-e152.	0.6	0
90	P333 Integration of Palliative Care for Patients with Metastatic Breast Cancer: Have We Achieved Quality End-of-Life Care?. Journal of Pain and Symptom Management, 2016, 52, e152.	0.6	1

#	Article	IF	CITATIONS
91	Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06) Tj ETQq1 The, 2016, 17, 727-737.	1 0.7843 5.1	14 rgBT /Ov 172
92	Longâ€term outcomes following postâ€operative radiotherapy for Stage I/ <scp>II</scp> testicular seminoma – an Australasian singleâ€institution experience. Journal of Medical Radiation Sciences, 2016, 63, 161-169.	0.8	2
93	Predictors and rate of adjuvant radiation therapy following radical prostatectomy: A report from the <scp>P</scp> rostate <scp>C</scp> ancer <scp>R</scp> egistry. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 247-254.	0.9	14
94	Development of an International Prostate Cancer Outcomes Registry. BJU International, 2016, 117, 60-67.	1.3	31
95	Gleason group concordance between biopsy and radical prostatectomy specimens: A cohort study from Prostate Cancer Outcome Registry – Victoria. Prostate International, 2016, 4, 145-151.	1.2	41
96	Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia. BMC Urology, 2016, 16, 54.	0.6	16
97	Caregivers' information needs and their â€~experiences of care' during treatment are associated with elevated anxiety and depression: a cross-sectional study of the caregivers of renal cancer survivors. Supportive Care in Cancer, 2016, 24, 4177-4186.	1.0	34
98	Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset. BMC Research Notes, 2016, 9, 37.	0.6	4
99	Prospective evaluation of patientâ€reported quality of life outcomes after external beam radiation treatment for prostate cancer in <scp>V</scp> ictoria: A cohort study by the <scp>V</scp> ictorian <scp>P</scp> rostate <scp>C</scp> ancer <scp>R</scp> egistry. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 420-427.	0.9	5
100	Comparison of oncological and healthâ€related quality of life outcomes between open and robotâ€assisted radical prostatectomy for localisedÂprostate cancer – findings from the populationâ€based Victorian Prostate Cancer Registry. BJU International, 2016, 118, 563-569.	1.3	29
101	Comparison of Patient-Reported Quality-of-Life and Complications in Men With Prostate Cancer, Between Two Modes of Administration. Clinical Genitourinary Cancer, 2016, 14, 284-289.	0.9	6
102	Increased prostate cancer specific mortality following radical prostatectomy in men presenting with voiding symptoms—A whole of population study. Prostate International, 2015, 3, 75-79.	1.2	5
103	The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the <scp>V</scp> ictorian Prostate Cancer Registry. BJU International, 2015, 115, 50-56.	1.3	80
104	Clinicopathological characteristics and management of prostate cancer in the human immunodeficiency virus (<scp>HIV</scp>)â€positive population: experience in an <scp>A</scp> ustralian major <scp>HIV</scp> centre. BJU International, 2015, 116, 5-10.	1.3	10
105	Predictors of prostate cancer specific mortality after radical prostatectomy: 10Âyear oncologic outcomes from the Victorian Radical Prostatectomy Registry. BJU International, 2015, 116, 66-72.	1.3	11
106	The state of <scp>TRUS</scp> biopsy sepsis: readmissions to Victorian hospitals with <scp>TRUS</scp> biopsyâ€related infection over 5 years. BJU International, 2015, 116, 49-53.	1.3	40
107	Practical considerations in the selection of seed strength for prostate implants. Journal of Applied Clinical Medical Physics, 2015, 16, 53-61.	0.8	2
108	Prevalence of Baseline Erectile Dysfunction (ED) in an Australian Cohort of Men with Localized Prostate Cancer. Journal of Sexual Medicine, 2015, 12, 1267-1274.	0.3	9

#	Article	IF	CITATIONS
109	A Whole of Population, Multiuser Series of High-Intensity Focused Ultrasound for Management of Localized Prostate Cancer: Outcomes and Implications. Journal of Endourology, 2015, 29, 844-849.	1.1	5
110	The influence of the dwell time deviation constraint (DTDC) parameter on dosimetry with IPSA optimisation for HDR prostate brachytherapy. Australasian Physical and Engineering Sciences in Medicine, 2015, 38, 55-61.	1.4	15
111	TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial Journal of Clinical Oncology, 2015, 33, 5007-5007.	0.8	3
112	Monitoring Quality of Care in Men Diagnosed with Prostate Cancer: Developing Consensus Quality Indicators Using Modified-Delphi Methodology. Journal of Epidemiology and Preventive Medicine, 2015, 1, .	0.2	1
113	Establishing tumour tracking accuracy in free-breathing respiratory gated SBRT of lung cancer. Journal of Physics: Conference Series, 2014, 489, 012041.	0.3	0
114	Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the Prostate Cancer Registry. BJU International, 2014, 114, 680-690.	1.3	39
115	Rural residency and prostate cancer specific mortality: results from the Victorian Radical Prostatectomy Register. Australian and New Zealand Journal of Public Health, 2014, 38, 449-454.	0.8	22
116	In vivo characterization and numerical simulation of prostate properties for non-thermal irreversible electroporation ablation. Prostate, 2014, 74, 458-468.	1.2	103
117	A <scp>P</scp> hase <scp>III</scp> trial to investigate the timing of radiotherapy for prostate cancer with highâ€risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage (<scp>RAVES</scp>) trial. BJU International, 2014, 113, 7-12.	1.3	104
118	Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncology, The, 2014, 15, 464-473.	5.1	392
119	The Victorian Lung Cancer Registry Pilot: Improving the Quality of Lung Cancer Care Through the Use of a Disease Quality Registry. Lung, 2014, 192, 749-758.	1.4	42
120	Long-term erectile function following permanent seed brachytherapy treatment for localized prostate cancer. Radiotherapy and Oncology, 2014, 112, 72-76.	0.3	18
121	Low Uptake of Upfront Autologous Transplantation for Myeloma in a Jurisdiction With Universal Health Care Coverage: A Population-Based Patterns of Care Study in Australia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 61-67.	0.2	5
122	Comparison of IPSA and HIPO inverse planning optimization algorithms for prostate HDR brachytherapy. Journal of Applied Clinical Medical Physics, 2014, 15, 256-266.	0.8	26
123	SU-C-16A-01: In Vivo Source Position Verification in High Dose Rate (HDR) Prostate Brachytherapy Using a Flat Panel Imager: Initial Clinical Experience. Medical Physics, 2014, 41, 90-90.	1.6	0
124	231 SURVIVAL ANALYSIS OF A WHOLE OF POPULATION STUDY FOR RADICAL PROSTATECTOMY IN THE PSA ERA. Journal of Urology, 2013, 189, .	0.2	0
125	Size of anal squamous cell carcinomas at diagnosis: a retrospective case series. International Journal of STD and AIDS, 2013, 24, 879-882.	0.5	25
126	Urethral strictures following high-dose-rate brachytherapy for prostate cancer: Analysis of risk factors. Brachytherapy, 2013, 12, 50-55.	0.2	81

#	Article	IF	CITATIONS
127	Systematic Review of Quality Improvement Interventions Directed at Cancer Specialists. Journal of Clinical Oncology, 2013, 31, 1583-1591.	0.8	12
128	The Prostate Cancer Registry: monitoring patterns and quality of care for men diagnosed with prostate cancer. BJU International, 2013, 111, E158-66.	1.3	61
129	Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy. Psycho-Oncology, 2013, 22, 2169-2176.	1.0	36
130	Factors associated with adherence to physical activity guidelines in patients with prostate cancer. Psycho-Oncology, 2013, 22, 2478-2486.	1.0	44
131	A randomised, doubleâ€blind, placeboâ€controlled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 81-88.	0.9	28
132	Contemporary management of renal cell carcinoma (<scp>RCC</scp>) in <scp>V</scp> ictoria: implications for longer term outcomes and costs. BJU International, 2013, 112, 36-43.	1.3	14
133	Source position verification and dosimetry in HDR brachytherapy using an EPID. Medical Physics, 2013, 40, 111706.	1.6	39
134	Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. Medical Journal of Australia, 2013, 198, 540-545.	0.8	74
135	Quality-of-life outcomes for prostate cancer treatment in Australia Journal of Clinical Oncology, 2013, 31, 143-143.	0.8	0
136	Comparative analysis of prostateâ€specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU International, 2012, 109, 22-29.	1.3	391
137	Australian & New Zealand Faculty of Radiation Oncology Genitoâ€Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 18-30.	0.9	18
138	What is optimal timing of post prostatectomy radiotherapy? Is adjuvant radiotherapy equivalent to early salvage radiotherapy? The "RAVES―phase III randomized clinical trial Journal of Clinical Oncology, 2012, 30, TPS4690-TPS4690.	0.8	2
139	Prostate-Specific Antigen Bounce After Permanent Iodine-125 Prostate Brachytherapy—An Australian Analysis. International Journal of Radiation Oncology Biology Physics, 2011, 79, 179-187.	0.4	23
140	High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. Brachytherapy, 2010, 9, 27-35.	0.2	72
141	Is Radiotherapy a Good Adjuvant Strategy for Men With a History of Cryptorchism and Stage I Seminoma?. International Journal of Radiation Oncology Biology Physics, 2010, 76, 65-70.	0.4	3
142	â€~GAP' in radiotherapy services in Australia and New Zealand in 2009. Journal of Medical Imaging and Radiation Oncology, 2010, 54, 287-297.	0.9	12
143	Effect of Intensity-Modulated Pelvic Radiotherapy on Second Cancer Risk in the Postoperative Treatment of Endometrial and Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 74, 539-545.	0.4	51
144	A whole of populationâ€based series of radical prostatectomy in Victoria, 1995 to 2000. Australian and New Zealand Journal of Public Health, 2009, 33, 527-533.	0.8	13

#	Article	IF	CITATIONS
145	Characterization of the pattern of sexual function after brachytherapy or radical prostatectomy suggests the importance of expectation management. Brachytherapy, 2008, 7, 121.	0.2	1
146	Qualitative research to improve patient perception of care: A prostate brachytherapy patient focus group. Brachytherapy, 2008, 7, 193.	0.2	0
147	3D Radiotherapy Can Be Safely Combined With Sandwich Systemic Gemcitabine Chemotherapy in the Management of Pancreatic Cancer: Factors Influencing Outcome. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1438-1446.	0.4	11
148	Effect of Radiotherapy Volume and Dose on Secondary Cancer Risk in Stage I Testicular Seminoma. International Journal of Radiation Oncology Biology Physics, 2008, 70, 853-858.	0.4	52
149	An Update of the Phase III Trial Comparing Whole Pelvic to Prostate Only Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression: Updated Analysis of RTOG 94-13, With Emphasis on Unexpected Hormone/Radiation Interactions: In Regard to Lawton et al. (Int J Radiat Oncol Biol Phys) Tj ETQq1	1 ⁰ 0 ⁴ 78431	L4 rgBT /C
150	Accrediting radiation technique in a multicentre trial of chemoradiation for pancreatic cancer. Journal of Medical Imaging and Radiation Oncology, 2008, 52, 598-604.	0.9	2
151	Re: Finney G, Haynes A-M, Cross P, et al: Cross-Sectional Analysis of Sexual Function After Prostate Brachytherapy (Urology 66: 377–381, 2005). Urology, 2008, 71, 364.	0.5	0
152	Post-prostatectomy radiation therapy: Consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiotherapy and Oncology, 2008, 88, 10-19.	0.3	174
153	Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncology, The, 2007, 8, 475-487.	5.1	843
154	15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. International Journal of Radiation Oncology Biology Physics, 2007, 67, 57-64.	0.4	196
155	Assessing mood and general health-related quality of life among men treated in Australia for localized prostate cancer. International Journal of Urology, 2007, 14, 311-316.	0.5	4
156	Long-Term Outcomes of Patients with Localized Rectal Cancer Treated with Chemoradiation or Radiotherapy Alone Because of Medical Inoperability or Patient Refusal. Diseases of the Colon and Rectum, 2007, 50, 2032-2039.	0.7	59
157	Disease-specific quality of life among patients with localized prostate cancer: an Australian perspective. BJU International, 2006, 97, 1179-1183.	1.3	12
158	MANAGEMENT OF MUSCLE-INVASIVE BLADDER CANCER IN VICTORIA, 1990-1995. ANZ Journal of Surgery, 2006, 76, 113-119.	0.3	8
159	An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk. International Journal of Radiation Oncology Biology Physics, 2006, 65, 351-357.	0.4	31
160	Alternative explanations for T-cell response to in-situ gene therapy for prostate cancer: In reply to Fugita et al. (Int J Radiat Oncol Biol Phys 2006;65:84–90). International Journal of Radiation Oncology Biology Physics, 2006, 66, 1599.	0.4	0
161	A simple technique for determining accurate urethral dosimetry after seed brachytherapy for prostate cancer. Brachytherapy, 2006, 5, 27-31.	0.2	4
162	MANAGEMENT OF SUPERFICIAL BLADDER CANCER IN VICTORIA: 1990 AND 1995. ANZ Journal of Surgery, 2005, 75, 270-274.	0.3	5

#	Article	IF	CITATIONS
163	Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology, The, 2005, 6, 659-668.	5.1	876
164	Activation of Thymic Regeneration in Mice and Humans following Androgen Blockade. Journal of Immunology, 2005, 175, 2741-2753.	0.4	431
165	Androgen Suppression Plus Radiation for Prostate Cancer. JAMA - Journal of the American Medical Association, 2004, 292, 2581.	3.8	0
166	What defines intermediate-risk prostate cancer? Variability in published prognostic models. International Journal of Radiation Oncology Biology Physics, 2004, 58, 11-18.	0.4	18
167	Human immunodeficiency virus-related primary central nervous system lymphoma. Cancer, 2004, 100, 2627-2636.	2.0	123
168	Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1082-1087.	0.4	30
169	Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy. Radiotherapy and Oncology, 2004, 73, 33-38.	0.3	52
170	What to do for prostate cancer patients with a rising PSA?—a survey of Australian practice. International Journal of Radiation Oncology Biology Physics, 2003, 55, 986-991.	0.4	27
171	In regard to Pollack et al., prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. IJROBP 2002;53:1097–1105. International Journal of Radiation Oncology Biology Physics, 2003, 55, 1461.	0.4	1
172	Rectal cancer in Victoria in 1994: Patterns of reported management. ANZ Journal of Surgery, 2002, 72, 265-270.	0.3	9
173	Phase II clinical trial of preoperative combined chemoradiation for T3 and T4 resectable rectal cancer. Diseases of the Colon and Rectum, 2001, 44, 1113-1122.	0.7	47
174	A double exposed portal image comparison between electronic portal imaging hard copies and port films in radiation therapy treatment setup confirmation to determine its clinical application in a radiotherapy center. International Journal of Radiation Oncology Biology Physics, 2001, 49, 191-198.	0.4	12
175	Prostate cancer in Victoria in 1993: patterns of reported management. Medical Journal of Australia, 2000, 172, 270-274.	0.8	14
176	Adjuvant radiotherapy for DCIS. Lancet, The, 2000, 355, 2072.	6.3	0
177	Adjuvant radiotherapy for DCIS. Lancet, The, 2000, 355, 2071.	6.3	4
178	Review on bladder cancer. BMJ: British Medical Journal, 1999, 318, 875-875.	2.4	2
179	Radical surgery versus radiotherapy for stage Ib-lla cervical cancer. Lancet, The, 1997, 350, 1179.	6.3	2
180	Surgery for oesophageal squamous cell carcinoma. Lancet, The, 1994, 343, 1099.	6.3	0

#	Article	IF	CITATIONS
181	Blindness in patients after external beam irradiation for pituitary adenomas: Two cases occurring after small daily fractional doses. Clinical Oncology, 1991, 3, 291-294.	0.6	23
182	Diagnosis of thymoma by fine-needle aspiration cytology: Light and electron microscopic study of a case. Diagnostic Cytopathology, 1987, 3, 166-169.	0.5	9
183	Variations in whole brain radiation therapy fractionation for brain metastases in Victoria. Journal of Medical Imaging and Radiation Oncology, 0, , .	0.9	1